Heska Corp (HSKA) COO Jason A. Napolitano Sells 2,500 Shares of Stock
Heska Corp (NASDAQ:HSKA) COO Jason A. Napolitano sold 2,500 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $111.50, for a total value of $278,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jason A. Napolitano also recently made the following trade(s):
- On Monday, July 9th, Jason A. Napolitano sold 1,200 shares of Heska stock. The stock was sold at an average price of $110.00, for a total value of $132,000.00.
Shares of HSKA opened at $109.08 on Tuesday. The firm has a market cap of $820.03 million, a PE ratio of 53.14 and a beta of 0.52. Heska Corp has a one year low of $56.59 and a one year high of $112.25.
A number of hedge funds have recently made changes to their positions in HSKA. FMR LLC boosted its stake in Heska by 81.9% during the second quarter. FMR LLC now owns 459,211 shares of the medical research company’s stock valued at $47,662,000 after buying an additional 206,814 shares in the last quarter. Fred Alger Management Inc. boosted its stake in Heska by 157.4% during the second quarter. Fred Alger Management Inc. now owns 277,687 shares of the medical research company’s stock valued at $28,821,000 after buying an additional 169,804 shares in the last quarter. Redmile Group LLC boosted its stake in Heska by 48.8% during the second quarter. Redmile Group LLC now owns 354,776 shares of the medical research company’s stock valued at $36,822,000 after buying an additional 116,330 shares in the last quarter. BlackRock Inc. boosted its stake in Heska by 10.6% during the second quarter. BlackRock Inc. now owns 1,027,636 shares of the medical research company’s stock valued at $106,657,000 after buying an additional 98,875 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in Heska during the first quarter valued at about $3,493,000. 89.17% of the stock is owned by institutional investors and hedge funds.
Several brokerages have weighed in on HSKA. BidaskClub lowered Heska from a “buy” rating to a “hold” rating in a research report on Tuesday, August 28th. TheStreet lowered Heska from a “b” rating to a “c+” rating in a report on Monday, August 20th. Zacks Investment Research lowered Heska from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. ValuEngine lowered Heska from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Finally, Benchmark started coverage on Heska in a report on Thursday, July 19th. They set a “buy” rating and a $120.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $107.50.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.